3 ASX 200 directors who have been buying up their company shares this week

These insiders apparently like the look of their company's stock.

The S&P/ASX 200 Index (ASX: XJO) has been on the up and up this week, gaining around 2.5% over the last four sessions. There's been plenty of buying activity among ASX 200 insiders in that time, with three forking out for notable parcels of their company's shares.

Indeed, one ASX 200 insider spent $272,000 to bolster their holding.

So, which market favourites have been the subject of insider trading this week? Keep reading to find out.

Three businesspeople leap high with the CBD in the background.

Image source: Getty Images

3 ASX 200 directors snapping up their company's shares

CSL Limited (ASX: CSL) was the first ASX 200 share bought by insiders this week.

CSL director Alison Watkins indirectly purchased 1,000 of the company's shares on-market on Monday, paying $272 per share to do so.

That saw the director forking out a total of $272,000. Watkins walked away from the transaction with an indirect interest in 3,076 CSL shares.

The ASX 200 company's share price has since lifted 1.4% to trade at $275.86 at the time of writing.

There's also been insider buying at ASX 200 property group Stockland Corporation Ltd (ASX: SGP) this week.

Stockland director Stephen Newton indirectly snapped up 30,000 shares in the company on-market on Monday, paying around $3.30 apiece to do so. That leaves the parcel with a value of $99,000 and Newton holding 70,000 shares in the ASX 200 company.

That's already paid off for the director. The Stockland share price currently trades 4.5% higher than Newton's price at $3.45.

Finally, an ASX release revealed Transurban Group (ASX: TCL) CEO and director Scott Charlton has indirectly increased his holding in the ASX 200 toll road operator's shares.

Charlton's interest in the company increased by 15,000 stocks, each bought on-market for $12.45, on Monday.

The parcel cost a total of $186,750 and left the director with 16,500 of the company's stocks.  

That's proved to be a short-term winner. The Transurban share price is now trading at $13.07 – 4.9% higher than the price paid by the director.

Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on ASX Share Market News

Young successful engineer, with blueprints, notepad, and digital tablet, observing the project implementation on construction site and in mine.
Broker Notes

Why the Paladin Energy share price "doesn't make sense"

This uranium stock could be set for a major re-rating.

Read more »

Girl with painted hands.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a remarkably positive end to the trading week.

Read more »

Two miners standing together.
Broker Notes

3 ASX 200 mining shares to buy with 41% to 79% upside ahead: broker

The green energy transition and other factors are providing strong growth drivers for mining.

Read more »

Happy miner with his arms folded.
Broker Notes

Buy, hold, sell: Paladin Energy, Fortescue, Rio Tinto shares

Let's take a look at some new ratings from Morgans.

Read more »

a man in a business suite throws his arms open wide above his head and raises his face with his mouth open in celebration in front of a background of an illuminated board tracking stock market movements.
Broker Notes

9 ASX 200 shares experts are backing for growth amid market weakness

Brokers retained a positive view on BHP, CSL, Telstra, Xero, and other shares this week. 

Read more »

One large yellow sphere on one side of a white seesaw, with a small yellow sphere on the other side.
Opinions

I investigated 3 ASX shares that have fallen sharply. Are they bargains or value traps?

I've given my verdict on three depressed high-profile stocks.

Read more »

Medical workers examine an x-ray or scan in a hospital laboratory.
Broker Notes

This ASX biotech could rise 40% or 750%, depending on who you ask

A poor quarter has reduced expectations, but there's still plenty of upside.

Read more »

Person pointing at an increasing blue graph which represents a rising share price.
Opinions

These are the best 3 ASX growth shares I own and I'd buy more of today

I’m bullish about the earnings potential of these three ASX growth shares.

Read more »